0001144204-11-053701.txt : 20110919 0001144204-11-053701.hdr.sgml : 20110919 20110919140834 ACCESSION NUMBER: 0001144204-11-053701 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110919 DATE AS OF CHANGE: 20110919 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ELITE PHARMACEUTICALS INC /DE/ CENTRAL INDEX KEY: 0001053369 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223542636 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-59693 FILM NUMBER: 111097007 BUSINESS ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 BUSINESS PHONE: 2017502646 MAIL ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MIDSUMMER INVESTMENT LTD CENTRAL INDEX KEY: 0001312269 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 485 MADISON AVENUE 23RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-584-2140 MAIL ADDRESS: STREET 1: 485 MADISON AVENUE 23RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SC 13G/A 1 v235199_sc13ga.htm AMENDMENT TO SCHEDULE 13G Unassociated Document
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 
AMENDMENT NO. 2

SCHEDULE 13G
(RULE 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)


ELITE PHARMACEUTICALS, INC.
(Name of Issuer)


COMMON STOCK, $0.001 PAR VALUE
(Title of Class of Securities)

28659T200
(CUSIP Number)

April 12, 2011
(Date of event which requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)


(Continued on following pages)
(Page 1 of 5 Pages)
 
 
 
 
Page 2 of 5 Pages
 
1.
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Midsummer Investment Ltd.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
(a) o
(b) x
3.
SEC USE ONLY
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION:
 
Bermuda
NUMBER OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
 
0
6.
SHARED VOTING POWER
 
None.
7.
SOLE DISPOSITIVE POWER
 
0
8.
SHARED DISPOSITIVE POWER
 
None.
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.00%
12.
TYPE OF REPORTING PERSON:
 
OO

 
 
 
 
Page 3 of 5 Pages

 
Item 1(a).
Name of Issuer.
 
Elite Pharmaceuticals, Inc. (the “Issuer”)
 
Item 1(b).
Address of Issuer’s Principal Executive Offices.
 
165 Ludlow Avenue, Northvale, New Jersey 07647
 
Item 2(a).
Names of Person Filing.
 
 
Midsummer Investment Ltd. (“Midsummer Investment”)
 

Item 2(b).
Address of Principal Business Office, or if none, Residence.
 
 
Midsummer Investment Ltd.
c/o Midsummer Capital, LLC
295 Madison Ave, 38th Floor
New York, NY  10017
 
 
Item 2(c).
Citizenship or Place of Organization.
 
 
Bermuda
 
Item 2(d).
Title of Class of Securities.
 
 
Common Stock, $0.001 par value (the “Common Stock”)
 
Item 2(e).
CUSIP Number.
 
 
28659T200 
 
Item 3.
If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a:
 
 
Not applicable.
 
Item 4.
Ownership.

This amendment No.2 to Schedule 13G is being filed to disclose that Midsummer Investment no longer beneficially owns any shares of Common Stock as of the date hereof.

Accordingly, for the purpose of this Statement:
 
(a)
Amount beneficially owned by Midsummer Investment: 0 shares of Common Stock of the Issuer.
 
(b)
Percent of Class: Midsummer Investment beneficially owns 0.00% of the Issuer’s issued and outstanding Common Stock.
 
(c)
Number of shares as to which Midsummer Investment has:
 
 
 
 
Page 4 of 5 Pages
 
 
(i)
Sole power to direct the vote: 0 shares of Common Stock of the Issuer.
 
(ii)
Shared power to vote or to direct the vote: None.
 
(iii)
Sole power to dispose or direct the disposition of the Common Stock: 0 shares of Common Stock of the Issuer.
 
(iv)
Shared power to dispose or direct the disposition of the Common Stock: None.

Item 5.
Ownership of Five Percent or Less of a Class.
 
 
x
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
 
Not applicable.
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
 
 
Not applicable.
 
Item 8.
Identification and Classification of Members of the Group.
 
 
Not applicable.
 
Item 9.
Notice of Dissolution of Group.
 
 
Not applicable.
 
Item 10.
Certification.
 
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction which could have that purpose or effect.
 
 
 
 
 
Page 5 of 5 Pages
 
 
SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
Date:  September 15, 2011
  
     
 
MIDSUMMER INVESTMENT LTD.
  
     
 
By:
/s/Michel A. Amsalem
  
   
Name: Michel A. Amsalem
  
   
Title:  President